4/A: Entera Bio CFO Receives Stock Options and Restricted Stock Units
SEC Form 4/A
Dana Yaacov-Garbeli, CFO of Entera Bio Ltd., received stock options and restricted stock units, and an amendment was filed to correct a previous reporting error regarding direct ownership.
Summary
- Dana Yaacov-Garbeli, the Chief Financial Officer of Entera Bio Ltd., filed an amended Form 4 to report changes in beneficial ownership.
- On April 19, 2024, she received 30,151 restricted stock units, vesting quarterly over one year, and 130,000 stock options, vesting over three years.
- The options have an exercise price of $1.99 and expire on April 19, 2034.
- The amendment corrects a previous filing that incorrectly stated direct ownership of ordinary shares and restricted stock units; these are actually held indirectly through A2Z Counseling Ltd., in which she owns a 33.33% interest and has effective control.
Sentiment
Score: 6
Explanation: The document is a routine disclosure of executive compensation. It's neutral to slightly positive as it indicates continued investment in the company's leadership.
Positives
- The grant of stock options and restricted stock units could incentivize the CFO to improve company performance.
- The vesting schedule aligns the CFO's interests with the long-term success of the company.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedules of the stock options and restricted stock units.
Industry Context
Stock option and restricted stock unit grants are common practices in the biotech industry to incentivize executives and align their interests with shareholders.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotechnology industry.
- Companies like Amgen, Gilead Sciences, and Biogen routinely grant stock options and restricted stock units to their executives.
- The vesting schedules described are typical, with vesting occurring over a period of 1-3 years.
Stakeholder Impact
- Shareholders may view the stock option and restricted stock unit grants as a positive sign, aligning management's interests with theirs.
- Employees may see this as a positive sign of investment in leadership.
Key Dates
| Date | Description |
|---|---|
| 04/19/2024 | Date of transaction: Grant of restricted stock units and stock options. |
| 04/23/2024 | Date of original Form 4 filing (amended). |
| 04/19/2025 | First anniversary of vesting commencement date for stock options (33% vesting). |
| 04/19/2034 | Expiration date of stock options. |
| 08/02/2024 | Date of amended filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.